Advisor OS LLC Purchases Shares of 2,962 AstraZeneca PLC $AZN

Advisor OS LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,962 shares of the company’s stock, valued at approximately $227,000.

A number of other institutional investors also recently modified their holdings of AZN. Cibc World Market Inc. increased its position in AstraZeneca by 21.5% in the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after acquiring an additional 11,398 shares in the last quarter. TD Asset Management Inc lifted its position in shares of AstraZeneca by 20.0% during the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after purchasing an additional 181,273 shares in the last quarter. Y Intercept Hong Kong Ltd grew its stake in shares of AstraZeneca by 111.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock valued at $5,113,000 after purchasing an additional 35,148 shares during the last quarter. AMG National Trust Bank increased its holdings in shares of AstraZeneca by 20.4% in the third quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after purchasing an additional 7,289 shares in the last quarter. Finally, Oxbow Advisors LLC raised its position in AstraZeneca by 96.2% in the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock worth $5,953,000 after purchasing an additional 38,043 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Up 2.3%

AZN opened at $208.72 on Friday. The firm’s fifty day moving average is $135.91 and its two-hundred day moving average is $102.20. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The firm has a market cap of $323.71 billion, a PE ratio of 69.34, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a twelve month low of $122.48 and a twelve month high of $212.71.

AstraZeneca Dividend Announcement

The firm also recently announced a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be paid a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s payout ratio is presently 74.83%.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent research reports. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. HSBC reissued a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a report on Wednesday, December 10th. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, January 6th. Finally, Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.